BACKGROUND: Although the mechanism of atazanavir (ATV)-related hyperbilirubinemia is well identified, its prevalence, risk factors, and association with transaminase flares have rarely been assessed in a large population from the "real life" setting. METHODS: Prospectively collected data on 2,404 patients from the Italian MASTER Cohort and the Italian ATV expanded access program database were examined. Uni- and multivariable Cox proportional hazards regression models were conducted to identify risk factors for grade >or= III hyperbilirubinemia during the administration of ATV. The risk of increased levels of serum alanine aminotransferase (ALT) was compared between patients with or without grade >or= III hyperbilirubinemia in a Cox regression analysis stratified by hepatitis C virus (HCV) serostatus. RESULTS: Grade III and IV hyperbilirubinemia were observed in 1,072 (44.6%) and 174 (7.2%) of the patients, respectively. Higher CD4+ T-cell counts, abnormal bilirubinemia at baseline, and ritonavir co-administration were associated with a higher risk of developing grade >or= III hyperbilirubinemia. In contrast, female gender, clinical class C, and non-nucleoside reverse transcriptase co-administration appeared to be protective. Higher bilirubinemia at baseline and the use of ritonavir were associated with a higher risk of grade IV hyperbilirubinemia. The occurrence of grade >or= III hyperbilirubinemia was not associated with severe hepatotoxicity (hazard ratio 1.00, 95% confidence interval 0.64-1.57; p = 0.997). CONCLUSIONS: Hyperbilirubinemia is a common side effect of an ATV pharmacotherapeutic regimen. However, grade IV increase in bilirubin was rarely found. In most cases, ATV hyperbilirubinemia appeared to be an innocent phenomenon as far as the risk of a subsequent increase in liver enzyme level is concerned.
BACKGROUND: Although the mechanism of atazanavir (ATV)-related hyperbilirubinemia is well identified, its prevalence, risk factors, and association with transaminase flares have rarely been assessed in a large population from the "real life" setting. METHODS: Prospectively collected data on 2,404 patients from the Italian MASTER Cohort and the Italian ATV expanded access program database were examined. Uni- and multivariable Cox proportional hazards regression models were conducted to identify risk factors for grade >or= III hyperbilirubinemia during the administration of ATV. The risk of increased levels of serum alanine aminotransferase (ALT) was compared between patients with or without grade >or= III hyperbilirubinemia in a Cox regression analysis stratified by hepatitis C virus (HCV) serostatus. RESULTS: Grade III and IV hyperbilirubinemia were observed in 1,072 (44.6%) and 174 (7.2%) of the patients, respectively. Higher CD4+ T-cell counts, abnormal bilirubinemia at baseline, and ritonavir co-administration were associated with a higher risk of developing grade >or= III hyperbilirubinemia. In contrast, female gender, clinical class C, and non-nucleoside reverse transcriptase co-administration appeared to be protective. Higher bilirubinemia at baseline and the use of ritonavir were associated with a higher risk of grade IV hyperbilirubinemia. The occurrence of grade >or= III hyperbilirubinemia was not associated with severe hepatotoxicity (hazard ratio 1.00, 95% confidence interval 0.64-1.57; p = 0.997). CONCLUSIONS:Hyperbilirubinemia is a common side effect of an ATV pharmacotherapeutic regimen. However, grade IV increase in bilirubin was rarely found. In most cases, ATVhyperbilirubinemia appeared to be an innocent phenomenon as far as the risk of a subsequent increase in liver enzyme level is concerned.
Authors: Robert L Murphy; Ian Sanne; Pedro Cahn; Praphan Phanuphak; Lisa Percival; Thomas Kelleher; Michael Giordano Journal: AIDS Date: 2003-12-05 Impact factor: 4.177
Authors: Jose Gatell; Dominique Salmon-Ceron; Adriano Lazzarin; Eric Van Wijngaerden; Francisco Antunes; Clifford Leen; Andrzej Horban; Victoria Wirtz; Linda Odeshoo; Monique Van den Dungen; Claudia Gruber; Emilio Ledesma Journal: Clin Infect Dis Date: 2007-04-25 Impact factor: 9.079
Authors: Kathleen Squires; Adriano Lazzarin; José M Gatell; William G Powderly; Vadim Pokrovskiy; Jean-François Delfraissy; Joseph Jemsek; Antonio Rivero; Willy Rozenbaum; Shannon Schrader; Michael Sension; Asda Vibhagool; Alexandra Thiry; Michael Giordano Journal: J Acquir Immune Defic Syndr Date: 2004-08-15 Impact factor: 3.731
Authors: Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Victoria Wirtz; Anna Rightmire; Linda Odeshoo; Colin McLaren Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Heather J Ribaudo; Eric S Daar; Camlin Tierney; Gene D Morse; Katie Mollan; Paul E Sax; Margaret A Fischl; Ann C Collier; David W Haas Journal: J Infect Dis Date: 2012-11-12 Impact factor: 5.226
Authors: Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2014-04 Impact factor: 2.089
Authors: R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas Journal: Clin Pharmacol Ther Date: 2015-11-09 Impact factor: 6.875